Terumo India Launches FineCross M3 in Cardiology Portfolio

Terumo India, the Indian arm of Terumo Corporation (TSE: 4543), a global leader in medical technology, announced the launch of FineCross M3 Coronary Micro-Guide Catheter in India. The latest-generation catheter raises the bar for percutaneous coronary intervention (PCI), offering cardiologists enhanced crossing ability, guidewire support, and navigability in complex lesions that often hamper procedural success.

With coronary artery disease (CAD) continuing to be the leading cause of death in India, and a rising proportion of patients presenting with complex lesions it highlights the urgent need for advanced interventional tools.  Addressing this challenge, FineCross M3 equips cardiologists to perform more efficient, predictable, and safer procedures, enhancing both clinical outcomes and procedural confidence.

Commenting on the launch Shishir Agarwal, President and Managing Director, Terumo India said, “Innovation at Terumo India is always guided by enabling physicians to deliver the best possible care to patients. With the launch of FineCross M3, we are proud to bring a globally trusted advancement in interventional cardiology to India. This milestone reflects not only our commitment to strengthening cardiovascular care in the country, but also Our Promise "Unwavering commitment to patients” that lies at the heart of everything we do.”

FineCross M3 integrates Terumo’s legacy of engineering excellence with new design enhancements that address real-world challenges in percutaneous coronary intervention (PCI).

Key features include:

• 1.7 Fr tapered distal tip for superior lesion crossability
• 15 cm floppy distal segment for exceptional trackability through tortuous vessels
• Tapered stainless-steel braided shaft for enhanced pushability and control
• Next-generation hydrophilic coating for unmatched lubrication and durability
• PTFE inner layer with radiopaque marker for smooth device delivery and precise visualization

Adding perspective on the product’s clinical relevance, Nitin Stephen Abel, Senior Director, Terumo Interventional Systems, Terumo India said, “FineCross™ M3 represents more than just a product launch, it reflects our continued focus on advancing cardiovascular care in India in line with Terumo’s mission of contributing to society through healthcare. Through globally trusted innovations, we aim to empower physicians in delivering better patient outcomes and create a meaningful impact where it matters most.”

Also Read: NABL Launches MELT Labs Programme for Last-Mile Healthcare

The launch of FineCross M3 adds to Terumo India’s growing portfolio of advanced interventional solutions, further strengthening its role in shaping the future of cardiovascular care in the country.

About Terumo India Private Limited

Terumo India is a rapidly growing medical devices company dedicated to advancing access to high-quality cardiac, vascular, and other medical devices for patients and healthcare practitioners in India. As part of Terumo Corporation, a global leader in medical technology headquartered in Tokyo, Japan, Terumo India upholds a mission rooted in 104 years of history: ‘Contributing to Society through Healthcare.’

Founded in 2013 and headquartered in Gurgaon, NCR Delhi, Terumo India has touched over 100,000 lives. The company is four times Great Place to Work certified and was also recognized as one of India’s Top 15 Workplaces in Pharmaceuticals, Healthcare, and Biotech in 2022. Terumo India also runs several acclaimed training and development programs, collaborating closely with customers and academic partners to address the skilling needs of India’s healthcare system.